News for Sanofi (SNYNF)

Sanofi (SNYNF, SNY) reported fourth quarter net income from continuing operations of 880 million euros compared to a loss of 119 million euros, prior year. Basic earnings per share from continuing operations was 0.

Shares of American drug maker, Novavax, Inc. (NVAX), were surging in the pre-market trade on Friday after the company announced a narrower loss for the first-quarter and a multi-million co-exclusive licensing deal with Sanofi (SNYNF,SNY), a French pharma major to commercialize Covid-19 vaccine.

(RTTNews) - French drug major Sanofi (SNYNF, SNY) reported Thursday a loss in its fourth quarter, compared to prior year's profit, despite higher ...

Sanofi (SNYNF, SNY) reported that its second quarter net income attributable to equity holders increased to 1.43 billion euros from 1.17 billion euros, last year.

Sanofi (SNYNF, SNY) reported that its second quarter net income attributable to equity holders increased to 1.43 billion euros from 1.17 billion euros, last year.

SPDW’s major investments performed exceptionally well over the past six months. Read more to see my thoughts on SPDW ETF and why it is a Hold.

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sanofi (SNYNF – Research Report) and Medios AG ...

(RTTNews) - French drug major Sanofi (SNYNF, SNY) reported Friday that its third-quarter net income, on IFRS basis, was 2.08 billion euros, down 1...

Read Sanofi (OTCMKTS:SNYNF) Short Interest Update at ETF Daily News

Read Sanofi (OTCMKTS:SNYNF) Short Interest Update at ETF Daily News

Waiving patent rights won’t be enough to launch massive vaccine campaigns in developing countries

Traders on the floor of the New York Stock Exchange. Spencer Platt/Getty Images European equities have outperformed MSCI's All Country Wo...

GuruFocus Article or News written by insider and the topic is about:

GuruFocus Article or News written by GF Value and the topic is about:

Drugmakers and government labs are developing doses easier to take and transport to tackle coronavirus variants and avert future pandemics

Drugmakers and government labs are developing doses easier to take and transport to tackle coronavirus variants and avert future pandemics.

The European Medicines Agency will conduct an accelerated review of Eli Lilly and Co's rheumatoid arthritis drug Olumiant for hospitalized COVID-19 patients getting oxygen, the agency said on... | April 29, 2021

France stocks higher at close of trade; CAC 40 up 0.53%

GuruFocus Article or News written by insider and the topic is about: